Pacific Biosciences Lowers FY2026 Sales Guidance from $165.000M-$175.000M to $155.000M-$165.000M vs $166.790M Est
Pacific Biosciences (NASDAQ: PACB ) lowers FY2026 sales outlook from $165.000 million-$175.000 million to $155.000 million-$165.000 million vs $166.790 million estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.